Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Depreciation & Amortization (CF) (2023 - 2025)

Tonix Pharmaceuticals Holding has reported Depreciation & Amortization (CF) over the past 3 years, most recently at $488000.0 for Q4 2025.

  • Quarterly results put Depreciation & Amortization (CF) at $488000.0 for Q4 2025, down 1.61% from a year ago — trailing twelve months through Dec 2025 was $1.9 million (down 43.73% YoY), and the annual figure for FY2025 was $1.9 million, down 43.73%.
  • Depreciation & Amortization (CF) for Q4 2025 was $488000.0 at Tonix Pharmaceuticals Holding, up from $461000.0 in the prior quarter.
  • Over the last five years, Depreciation & Amortization (CF) for TNXP hit a ceiling of $1.3 million in Q4 2023 and a floor of $461000.0 in Q3 2025.
  • Median Depreciation & Amortization (CF) over the past 3 years was $701500.0 (2023), compared with a mean of $801333.3.
  • Peak annual rise in Depreciation & Amortization (CF) hit 35.5% in 2024, while the deepest fall reached 60.67% in 2024.
  • Tonix Pharmaceuticals Holding's Depreciation & Amortization (CF) stood at $1.3 million in 2023, then crashed by 60.67% to $496000.0 in 2024, then decreased by 1.61% to $488000.0 in 2025.
  • The last three reported values for Depreciation & Amortization (CF) were $488000.0 (Q4 2025), $461000.0 (Q3 2025), and $483000.0 (Q2 2025) per Business Quant data.